Validating cancer drug targets

被引：107

作者：

Benson, John D. ^{[1
]}

Chen, Ying-Nan P. ^{[1
]}

Cornell-Kennon, Susan A. ^{[1
]}

Dorsch, Marion ^{[1
]}

Kim, Sunkyu ^{[1
]}

Leszczyniecka, Magdalena ^{[1
]}

Sellers, William R. ^{[1
]}

Lengauer, Christoph ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

来源：

NATURE | 2006年 / 441卷 / 7092期

关键词：

D O I：

10.1038/nature04873

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

引用

页码：451 / 456

页数：6

共 57 条

[1] Zebrafish as a cancer model system
Amatruda, JF
Shepard, JL
Stern, HM
Zon, LI
[J]. CANCER CELL, 2002, 1 (03) : 229 - 231
[2] Proteasomal degradation of the Fox01 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins
Aoki, M
Hao, J
Vogt, PK
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (37) : 13613 - 13617
[3] The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, KE
Argani, P
Samuels, Y
Silliman, N
Ptak, J
Szabo, S
Konishi, H
Karakas, B
Blair, BG
Lin, C
Peters, BA
Velculescu, VE
Park, BH
[J]. CANCER BIOLOGY & THERAPY, 2004, 3 (08) : 772 - 775
[4] Raf: A strategic target for therapeutic development against cancer
Beeram, M
Patnaik, A
Rowinsky, EK
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6771 - 6790
[5] Using Drosophila melanogaster to map human cancer pathways
Brumby, AM
Richardson, HE
[J]. NATURE REVIEWS CANCER, 2005, 5 (08) : 626 - 639
[6] Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci
Cool, M
Depault, F
Jolicoeur, P
[J]. GENES CHROMOSOMES & CANCER, 2006, 45 (02) : 191 - 202
[7] Mutations of the BRAF gene in human cancer
Davies, H
Bignell, GR
Cox, C
Stephens, P
Edkins, S
Clegg, S
Teague, J
Woffendin, H
Garnett, MJ
Bottomley, W
Davis, N
Dicks, N
Ewing, R
Floyd, Y
Gray, K
Hall, S
Hawes, R
Hughes, J
Kosmidou, V
Menzies, A
Mould, C
Parker, A
Stevens, C
Watt, S
Hooper, S
Wilson, R
Jayatilake, H
Gusterson, BA
Cooper, C
Shipley, J
Hargrave, D
Pritchard-Jones, K
Maitland, N
Chenevix-Trench, G
Riggins, GJ
Bigner, DD
Palmieri, G
Cossu, A
Flanagan, A
Nicholson, A
Ho, JWC
Leung, SY
Yuen, ST
Weber, BL
Siegler, HF
Darrow, TL
Paterson, H
Marais, R
Marshall, CJ
Wooster, R
[J]. NATURE, 2002, 417 (6892) : 949 - 954
[8] The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M
Buchdunger, E
Druker, BJ
[J]. BLOOD, 2005, 105 (07) : 2640 - 2653
[9] Transgenic expression of PML/RAR alpha impairs myelopoiesis
Early, E
Moore, MAS
Kakizuka, A
NasonBurchenal, K
Martin, P
Evans, RM
Dmitrovsky, E
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7900 - 7904
[10] Emens Leisha A, 2005, Am J Ther, V12, P243

← 1 2 3 4 5 6 →